Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.

🔗 Read more: https://www.cnbc.com/2026/02/24/healthy-returns-whats-next-for-novo-nordisks-obesity-drug-cagrisema.html

#News #Health #Biology #Medicine #Business